One of the highlights of the 2005 ASCO Meeting was the announcement of results of several clinical trials using Herceptin in an adjuvant setting.
What was presented was mostly raw data and it will take a while before it is organized and presented to the FDA. Fortunately Genentech and Roche has the talent and expertise to make this process as smooth as possible.
We are trying to get complete abstracts and will publish them as soon as they are received.